首页 | 本学科首页   官方微博 | 高级检索  
   检索      


Discovery of novel Cyclophilin D inhibitors starting from three dimensional fragments with millimolar potencies
Institution:1. Merck Healthcare, Merck KGaA, Frankfurter Str. 250, D-64293 Darmstadt, Germany;2. EMD Serono Research & Development Institute Inc., 45A Middlesex Turnpike, Billerica, MA 01821, USA;3. Edelris, 115 Avenue, Lacassagne, F-69003 Lyon, France;4. Proteros Biostructures GmbH, Bunsenstraße 7a, D-82152 Planegg-Martinsried, Germany
Abstract:Fragment-based screening by SPR enabled the discovery of chemical diverse fragment hits with millimolar binding affinities to the peptidyl-prolyl isomerase Cyclophilin D (CypD). The CypD protein crystal structures of 6 fragment hits provided the basis for subsequent medicinal chemistry optimization by fragment merging and linking yielding three different chemical series with either urea, oxalyl or amide linkers connecting millimolar fragments in the S1′ and S2 pockets. We successfully improved the in vitro CypD potencies in the biochemical FP and PPIase assays and in the biophysical SPR binding assay from millimolar towards the low micromolar and submicromolar range by >1000-fold for some fragment derivatives. The initial SAR together with the protein crystal structures of our novel CypD inhibitors provide a suitable basis for further hit-to-lead optimization.
Keywords:Cyclophilin D  Inhibitor  Fragment-screening  X-ray structure  Surface plasmon resonance  Structure-based design  Fragment-based lead discovery
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号